MX2022004341A - Conjugados de fosfolípido-flavaglina y métodos para usar los mismos para la terapia dirigida al cáncer. - Google Patents

Conjugados de fosfolípido-flavaglina y métodos para usar los mismos para la terapia dirigida al cáncer.

Info

Publication number
MX2022004341A
MX2022004341A MX2022004341A MX2022004341A MX2022004341A MX 2022004341 A MX2022004341 A MX 2022004341A MX 2022004341 A MX2022004341 A MX 2022004341A MX 2022004341 A MX2022004341 A MX 2022004341A MX 2022004341 A MX2022004341 A MX 2022004341A
Authority
MX
Mexico
Prior art keywords
phospholipid
methods
flavagline
same
cancer therapy
Prior art date
Application number
MX2022004341A
Other languages
English (en)
Inventor
Jarrod Longcor
Original Assignee
Cellectar Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectar Biosciences Inc filed Critical Cellectar Biosciences Inc
Publication of MX2022004341A publication Critical patent/MX2022004341A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se divulgan en la presente moléculas de éter de fosfolípido (PLE); además se proporcionan conjugados de fosfolípido-flavaglina ; el conjugado de fosfolípido-flavaglina puede incluir un PLE conjugado a una flavaglina a través de un enlazador; se proporcionan además en la presente métodos para tratar cáncer en un sujeto y métodos para dirigir un fármaco a un tumor o una célula de cáncer en un sujeto.
MX2022004341A 2019-10-10 2020-10-09 Conjugados de fosfolípido-flavaglina y métodos para usar los mismos para la terapia dirigida al cáncer. MX2022004341A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962913571P 2019-10-10 2019-10-10
PCT/US2020/055121 WO2021072300A1 (en) 2019-10-10 2020-10-09 Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy

Publications (1)

Publication Number Publication Date
MX2022004341A true MX2022004341A (es) 2022-08-10

Family

ID=75436788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004341A MX2022004341A (es) 2019-10-10 2020-10-09 Conjugados de fosfolípido-flavaglina y métodos para usar los mismos para la terapia dirigida al cáncer.

Country Status (10)

Country Link
EP (1) EP4041718A4 (es)
JP (1) JP2022551495A (es)
KR (1) KR20220080139A (es)
CN (1) CN114761389A (es)
AU (1) AU2020361679A1 (es)
BR (1) BR112022006739B1 (es)
CA (1) CA3154192A1 (es)
IL (1) IL291979A (es)
MX (1) MX2022004341A (es)
WO (1) WO2021072300A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044960B1 (en) * 2004-03-02 2013-11-20 Cellectar, Inc. Phospholipid analogue for the in vivo diagnosis of cancers
US20100120727A1 (en) * 2008-11-12 2010-05-13 Kyphia Pharmaceuticals, Inc. Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
ES2799411T3 (es) * 2009-06-12 2020-12-17 Cellectar Inc Compuestos alquilfosfolipídicos para el tratamiento de cáncer y obtención de imágenes y detección de células madre cancerosas
WO2013016658A1 (en) * 2011-07-27 2013-01-31 The Ohio State University Research Foundation Silvestrol, silvestrol analogs and uses thereof
WO2014106826A2 (en) * 2013-01-07 2014-07-10 Piramal Enterprises Limited Anthracycline analogue and uses thereof
FR3023290B1 (fr) * 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
PT3229810T (pt) * 2014-11-17 2020-08-27 Cellectar Biosciences Inc Análogos de éter fosfolipídico como veículos de medicamentos direcionados para o cancro
EP3464280B1 (en) * 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use

Also Published As

Publication number Publication date
JP2022551495A (ja) 2022-12-09
AU2020361679A1 (en) 2022-04-28
EP4041718A4 (en) 2023-12-20
KR20220080139A (ko) 2022-06-14
EP4041718A1 (en) 2022-08-17
WO2021072300A1 (en) 2021-04-15
BR112022006739A2 (pt) 2022-06-28
BR112022006739B1 (pt) 2024-01-23
CN114761389A (zh) 2022-07-15
IL291979A (en) 2022-06-01
CA3154192A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
CY1122855T1 (el) Θεραπευτικα συστατικα δεσμευσης κυτταρικης επιφανειας με αματοξινη για τη θεραπεια ογκου
ZA202004099B (en) Methylene carbamate linkers for use with targeted-drug conjugates
JOP20210074A1 (ar) مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها
MX2021015887A (es) Un conjugado de un agente citotóxico y una molécula de unión a células con enlazadores ramificados.
PH12019502545A1 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
WO2003106659A3 (en) TOXIN-APTAMER MOLECULES AND METHODS OF USE THEREOF
MX2020012997A (es) Conjugados de anticuerpo modulador de empalme-farmaco y metodos de uso.
NZ745069A (en) Pyrrolobenzodiazepines and conjugates thereof
PH12017500023A1 (en) Targeted conjugates and particles and formulations thereof
JOP20210289A1 (ar) مقترنات عقار - جسم مضاد مثبط لـmcl-1 وطرق لاستخدامها
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
MX2013003452A (es) Conjugados de amatoxina con enlazantes mejorados.
MX366503B (es) Derivados de amatoxina.
MX2019001302A (es) Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
WO2017210246A3 (en) Penicillamine conjugates and particles and formulations thereof
MX2020010741A (es) Conjugados de fosfolipido-flavaglina y metodos para usar los mismos para la terapia dirigida al cancer.
WO2022093800A3 (en) Carrier particle-drug conjugates, self-immolative linkers, and uses thereof
MX2019009121A (es) Antcuerpos anti-kaag1 o fragmento de union al antigeno del mismo para el tratamiento de cancer de mama triple negativo.
BR112023015561A2 (pt) Compostos imunoestimuiladores e conjugados
MX2015006931A (es) Terapia combinada para tratar cánceres her2-positivos.
MX2018012392A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
MX2022004341A (es) Conjugados de fosfolípido-flavaglina y métodos para usar los mismos para la terapia dirigida al cáncer.
CL2020002637A1 (es) Métodos de tratamiento de cáncer.
Kuijpers et al. Liposomes targeting tumour stromal cells